•  
  •  
  •  
  •  

2026-08-04 22:40:55

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore

Keywords Selected:  USFDA

Stock Report

  • Zydus Lifesciences Ltd receives EIR from the USFDA for its injectable facility with VAI classification
  • Dr. Reddy's Laboratories Receives U.S. FDA Approval for Rituximab Biosimilar
  • Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Prucalopride Tablets, 1 mg and 2 mg
  • Jeevan Scientific Technology Successfully Concludes USFDA Inspection with Zero 483 Observations
  • Glenmark Receives U.S. FDA Approval to Expand the Use of RYALTRIS® Nasal Spray for Children Aged 6 to Less Than 12 Years
  • Wanbury Limited gets 6 observations from USFDA after cGMP inspection at Tanuku facility
  • Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg
  • NATCO receives Tentative Approval for Olaparib Tablets from the U.S. FDA
  • USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA
  • Ajanta Pharma Ltd receives EIR from USFDA for Paithan facility
  • Lupin Receives EIR from U.S. FDA for its Somerset Facility with VAI Classification
  • US FDA inspection at Glenmark Pharmaceuticals Ltd's manufacturing facility in Goa, India
  • Completion of US FDA Inspection at Auroactive Pharma Pvt Ltd
  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapsone Gel, 5%
  • Lupin receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
  • Completion of US FDA Pre-Approval Inspection at Eugia Steriles Private Limited
  • Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Binimetinib Tablets, 45 mg
  • Classification of US FDA Inspection at Unit-III of Eugia Pharma Specialities Ltd, Pashamylaram as OAI
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Tretinoin Cream USP, 0.05%
  • USFDA inspection at Cipla Ltd's manufacturing facility in Verna, Goa, India
  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg
  • Concord Biotech Ltd receives ANDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg

Latest Post

  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025